Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Deferred Revenue, by Arrangement, Disclosure (Details)

Deferred Revenue, by Arrangement, Disclosure (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2017	Aug. 31, 2017
Balance - Beginning	$ 17,083	$ 12,500
Territorial License fees received	0	30,000
Advance payments on product sales	0	4,900
Earned revenue	(6,250)	(30,317)
Balance - Ending	$ 10,833	$ 17,083

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details